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An abundant amount of different treatment modalities has
been developed for treatment of chronic midportion
Achilles tendinopathy. Amongst them are injection treat-
ments with as corticosteroids, Polidocanol, autologous
blood, platelet-rich plasma, high-volume injections,
hyperosmolar dextrose, brisement, aprotinin and low-dose
heparin. The rationale behind these treatments is not
always clear. The goal of treatment in general is to relieve
symptoms. The main symptom is pain. Up to date, the
cause of pain in chronic midportion Achilles tendinopathy
has not been elucidated however. So what is the rationale
behind these treatments?
Corticosteroid injection has become obsolete in the
treatment of midportion Achilles tendinopathy, as tendon
rupture has been reported in various cases [1, 2]. The role
of chemical inﬂammation in this pathology is also a matter
of debate, and therefore there is no rationale for anti-
inﬂammatory treatment [3, 4]. Ultrasound-guided treatment
with Polidocanol (Ethoxysclerol) was ﬁrst described in
2002 [5] as an effective and promising method to obliterate
neovessels in and around the tendon, which were hypoth-
esized to be a possible cause of pain. Studies on patellar
tendinopathy, lateral epicondylitis, supraspinatus tendinitis,
and the effectiveness of larger doses in Achilles tendons
followed [6–9]. However, not all authors have been able to
reproduce a good outcome [10]. The blood vessels are
unlikely to be the cause of pain. So what is the rationale
behind this treatment?
Platelet-rich plasma (PRP) is possibly the current most
controversial in the line-up of minimally invasive treatment
options. PRP is deﬁned as ‘any elevated level of platelets’.
A PubMed search with ‘platelet-rich plasma’ generates
5,565 results. A search term such as ‘autologous blood’ or
typographic changes would add many more references.
Medical companies legitimately take business advantage of
thishype.Itiscurrentlyusedintendon,muscleandligament
repair, osteoarthritis, surgical wounds and chronic ulcers.
However, application has been confusing as each method
leads to a different product with different biological char-
acteristics and possible applications. There are at least four
different products: pure PRP, leucocyte- and PRP, pure
platelet-rich ﬁbrin, and leucocyte- and platelet-rich ﬁbrin.
Some of these products can be activated or non-activated
[11]. Many types of platelet collectors have been developed,
and platelet concentration varies from 1.6–4.4 fold between
suppliers compared to whole blood [12]. One of the goals
seems to be to develop a technique that collects the highest
concentrationofplatelets. Autologouswhole bloodandPRP
havebeenusedinmidportionAchillestendinopathywiththe
aim of providing growth factors to promote healing in areas
of degeneration. However if effective, the questions arise:
whatconcentration would sufﬁce,howlongdoplateletsstay
where injected and what is their half-life? Supporting the
hypothesis that tendinopathy develops due to a failed
chemical healing response would then inducing a new
chemical reaction sufﬁce? Or are we trying to induce a
chemical response in a neurogenic area? Moreover, in case
of chronic midportion Achilles tendinopathy, the exact
location of injection is not always clearly described. Is it
possible to inject a substance inside the opaque but
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area really the cause of complaints? Several studies have
reported intratendinous changes in up to 34% of cadaver
specimens, ultrasound and MRI images of patients without
complaints [13–18]. A long-term follow-up study published
by Alfredson and co-workers revealed persistent structural
abnormalities and thickening of the tendon 13 years after
intratendinous surgery for Achilles tendinopathy, whereas
all patients were satisﬁed with the results and went back to
Achilles tendon loading activities without restrictions [13].
Ifthepaindoesnotcomefromthetendonproper,wheredoes
it originate? Recently various studies have shown ingrowth
of sensory- and sympathetic nerves accompanying neoves-
sels from the paratenon with release of nociceptive sub-
stances. Denervating the Achilles tendon by release of the
peritendineum would hereby hypothetically sufﬁce to
relievepain.Sincepainisthepredominantsymptominthese
patients, and it has never been demonstrated that patients
with tendinopathy are more prone to rupture, this approach
should be sufﬁcient for obtaining a good clinical outcome.
A minimally invasive technique such as high-volume
injection has been successfully performed to produce local
mechanical effects in order to release the adhesions formed
between peritendineum and tendon proper, thereby oblit-
erating neovascularisation and accompanying neonerves.
Brisement, ﬁrst described in 1997 [19], was initially meant
to interrupt the degenerative cycle of the tendon proper by
initiating a healing cascade, but in essence seems equiva-
lent to current high-volume injections. Now, could not a
combination of these two theories, old and new, be the
result of all injections? Meaning that no matter what we
introduce, an inﬂammatory response will be generated?
This can be illustrated by a randomized study by De Vos
et al., where injection of PRP was compared with saline,
producing an equivalent outcome [20]. Corticosteroid
injections for lateral epicondylitis did not provide any long-
term beneﬁt compared with placebo [21]. Brown et al.
performed a double-blind placebo-controlled trial in
patients with Achilles tendinopathy, where aprotinin was
compared with placebo, showing no statistically signiﬁcant
beneﬁt [22].
Until now, an evidence based algorithm for the (con-
servative) management of midportion Achilles tendinopa-
thy is unknown. Research on Achilles tendon-related
problems is ongoing. Further research should focus on the
cause of pain in patients with chronic midportion Achilles
tendinopathy. Recognising the cause of pain will help to
further deﬁne therapeutic strategies.
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